Work

Biased Agonism at µ-Opioid Receptor - The Quest for Safer Analgesics

Year: 2019
Type: dissertation
Abstract: Opioids are our most potent antinociceptive drugs, but their use is limited by adverse effects.Among the adverse effects are addiction, constipation and respiratory depression.In this thesis I review the current literature on biased µ-opioid receptor agonists and their potential for providing safer analgesia.Biased agonists activate one signaling effector over another.Among G-protein-coupled receptors, biased agonism is often used to denote an agonist that activates either G-protein-dependent signaling or β-arrestin-dependent signaling (G-protein-independent signaling).For the μ-opioid receptor, an agonist that activate the G-protein without recruiting β-arrestin-2 has been proposed to cause less respiratory depression, less addiction, less tolerance, less constipation and less opioid induced hyperalgesia.From the available literature I found substantial evidence for less respiratory depression by biased µ-opioid receptor agonists relative to classical opioids, while the data regarding constipation, addiction, tolerance and opioid induced hyperalgesia was less clear.Nevertheless, respiratory depression is the cause of death from opioid overdoses, hence a potent analgesic drug without this effect would be a great advancement.This far, no G-protein biased µ-opioid receptor agonist has reached the market, but a few is in development.The one that has come furthest is oliceridine by Trevena, which was recently rejected by the FDA.Trevena is still developing oliceridine, and they have another compound, TRV734, that possibly enter phase 2 studies soon.Also, Mebias Discovery has announced that they are developing two compounds that has shown a higher degree of bias and less respiratory depression than oliceridine in preclinical experiments.
Institution: University of Oslo
Language: English
Open Access status: green
OpenAlex ID: W3041641864
Cites: 74
Cited by:
Related to: 10